The Europe non-alcoholic steatopatitis market is expected to reach US$ 6,765.21 million by 2028 from US$ 496.83 million in 2021. The market is estimated to grow at a CAGR of 45.2% from 2021 to 2028.

Non-Alcoholic Steatohepatitis (NASH) remains an under-recognized and underdiagnosed liver condition despite affecting over 115 million people globally. Raising awareness among both the general public and primary care physicians (PCPs) is crucial for early detection, timely referrals, and structured patient care pathways. Increased recognition can significantly expand the patient pool by identifying individuals at risk and directing them to specialists for further evaluation.

To address this gap, several global initiatives have emerged. On June 12, 2018, the NASH Education Program launched the first public education campaign on “International NASH Day,” aiming to highlight the severity of non-alcoholic fatty liver disease (NAFLD) and its advanced form, NASH. Building on this momentum, the digital platform NASH 24X7 marked International NASH Day on June 12, 2019, by launching targeted awareness campaigns. These efforts included healthcare professional (HCP) support programs, patient education initiatives, and widespread media outreach via press and television coverage.

NASH 24X7 also introduced the "NASH Crusaders," who partnered with HCPs across India to host numerous educational workshops. These events focused on liver health and emphasized the importance of lifestyle modifications in preventing NAFLD and NASH. By engaging local communities and professionals, these workshops aimed to empower patients through knowledge and preventive strategies.

The campaign effectively utilized digital and print media to reach broader audiences, highlighting the growing importance of digital health education in managing chronic diseases. With increasing global awareness and strategic interventions, the Europe non-alcoholic steatopatitis market is projected to grow at a strong compound annual growth rate (CAGR) over the forecast period.

Through sustained awareness campaigns and educational outreach, improving liver health and early detection of NASH is becoming a global health priority, paving the way for more structured treatment pathways and better patient outcomes.

The Europe non-alcoholic steatopatitis market is a significant segment within the broader liver disease treatment landscape, driven by the increasing prevalence of obesity and related metabolic disorders. Here's a breakdown of its segmentation and key players, based on the provided information:

Europe non-alcoholic steatopatitis market Segmentation:

Europe non-alcoholic steatopatitis market Product Type:

• Vitamin E and Pioglitazone
• Ocaliva (Obeticholic Acid)
• Elafibranor
• Selonsertib & Cenicriviroc (expected to be the fastest-growing segment)
• Others (including other investigational and approved therapies)

Europe non-alcoholic steatopatitis market Application:

• Treatment (dominated the market in 2020)
• Diagnosis

Europe non-alcoholic steatopatitis market Sales Channel:

• Hospital Pharmacy
• Online Provider
• Retail Pharmacy (dominated the market in 2020)

Europe non-alcoholic steatopatitis market Country:

• Germany (dominated the market in 2020)
• The UK
• France
• Italy
• Spain
• Rest of Europe

Leading Companies in the Europe non-alcoholic steatopatitis market:

• Cadila Pharmaceutical
• Intercept Pharmaceutical
• Novartis AG
• Galmed Pharmaceutical
• GENFIT
• ONE WAY LIVER SI
• BioPredictive S.A.S
• Siemens Healthineers AG
• Laboratory Corporation of America Holdings

Additional Insights from Search Results: Europe non-alcoholic steatopatitis market

Market Size & Growth:As per our report Europe Non-Alcoholic Steatopatitis Market, the market size is valued at US$ 496.83 Million in 2021, projecting it to reach US$ 6,765.21 Million by 2028. This translates to a CAGR of approximately 45.2% during the forecast period.

Key Drivers: The increasing prevalence of obesity globally is a major growth factor for the NASH treatment market.

Challenges: A major challenge is the lack of appropriate, FDA-approved treatments that can halt or reverse the progression of hepatic fibrosis, cirrhosis, and hepatocellular carcinoma.

Emerging Trends:

• Increased interest in non-invasive diagnostics.
• Development of novel therapies and pharmacological treatments targeting various metabolic, inflammatory, and fibrotic pathways.
• Shift towards combination therapies due to the complex pathogenesis of NASH.
• Rising adoption of telemedicine and e-commerce platforms for healthcare products, driving the online providers segment.

Specific Company Activities:

• Intercept Pharmaceuticals: Their lead product is Ocaliva (obeticholic acid, OCA), though its marketing authorization in Europe was revoked in August 2024. They were acquired by Alfasigma S.p.A.
• Novartis AG: Has a development portfolio in non-viral liver diseases, including NASH, and has entered clinical collaborations to evaluate combination therapies.
• Galmed Pharmaceuticals: Focused on developing Aramchol, with recent patent grants for combination therapy with Resmetirom. They are also exploring broader cardiometabolic indications.
• GENFIT: Has a diagnostic franchise including NIS2+® in Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) and a rapidly expanding R&D portfolio in liver diseases. Their product elafibranor (Iqirvo®) has recently received pricing and reimbursement approval in Italy.
• ONE WAY LIVER S.L.: A biotechnology company offering diagnostic products and metabolomics services for liver diseases, including OWLiver for steatosis and NASH diagnosis.
• BioPredictive S.A.S: Offers non-invasive diagnostic tests for liver diseases, including NASH-FibroTest, SteatoTest, and NashTest.
• Siemens Healthineers AG & Laboratory Corporation of America Holdings (Labcorp): These companies are involved in broader healthcare diagnostics and services, which would include solutions and testing relevant to NASH diagnosis and monitoring.

About Us:

Business Market Insights is a market research platform that provides subscription service for industry and company reports. Our research team has extensive professional expertise in domains such as Electronics & Semiconductor; Aerospace & Defense; Automotive & Transportation; Energy & Power; Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals & Materials; and Technology, Media, & Telecommunications.

Author’s Bio:

Suryakant Gadekar

Senior Market Research Expert at Business Market Insights